Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273
Open accessAbstract
Comparison of SARS-CoV-2 Antibody Response Following Vaccination With BNT162b2 and mRNA-1273The SARS-CoV-2 messenger RNA (mRNA) vaccines BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have each shown more than 90% efficacy in preventing COVID-19 illness 1,2 but, to our knowledge, humoral immune responses have not been compared directly.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The mRNA vaccine clinical trials were not powered to address severe disease, including complications after hospitalization.
“The mRNA vaccine clinical trials were not powered to address severe disease, including complications after hospitalization.29,30”
From Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity (2021) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works
Decreased SARS-CoV-2 viral load following vaccination
Levine-Tiefenbrun, M., Yelin, I., Katz, R., Herzel, E., Golan, Z., Schreiber, L., Wolf, T., Nadler, V., Ben-Tov, A., Kuint, J., et al. (2021) · doi:10.1101/2021.02.06.21251283 · Cited by 514 · see citing works
Flagged first, then by citations
Research works printed but not linked: 5
- Furuta S, Nakagomi D, Kobayashi Y, et al; LoVAS Collaborators. Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial. JAMA. 2021; 325(21):2178-2187. doi:10.1001/jama.2021.6615 · DOI
- Jones RB, Tervaert JW, Hauser T, et al; European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211-220. doi:10.1056/NEJMoa0909169 · DOI
- Stone JH, Merkel PA, Spiera R, et al; RAVE-ITN Research Group. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010; 363(3):221-232. doi:10.1056/NEJMoa0909905 · DOI
- Walsh M, Merkel PA, Peh CA, et al; PEXIVAS Investigators. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med. 2020; 382(7):622-631. doi:10.1056/NEJMoa1803537 · DOI
- Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021; 384(7):599-609. doi:10.1056/NEJMoa2023386 · DOI · Paper page
- Authors
- Steensels, D., Pierlet, N., Penders, J., Mesotten, D., & Heylen, L.
- Affiliations
- Ziekenhuis Oost-Limburg (BE)
- Ziekenhuis Oost-Limburg, Genk, Belgium
- Corresponding author
- Steensels, Deborah
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-10-19
- Volume
- 326
- Issue
- 15
- Pages
- 1533
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC8406205
- OpenAlex
- W3196397911
- Cited by
- 351
- References
- 3
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 38 · 2023: 77 · 2022: 180 · 2021: 38
- FWCI
- 26.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- SARS-CoV-2, COVID-19 pandemic, BNT162b2, mRNA-1273, mRNA vaccines, humoral immune response, antibody response, vaccine comparison, vaccine efficacy
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, 2019-nCoV Vaccine mRNA-1273, Adult, Antibodies, Viral, Antibody Formation, Female, Health Personnel, Humans, Male, Prospective Studies, Vaccination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
